Aprea Therapeutics Inc. announced early clinical proof-of-concept results from its ongoing Phase 1 ACESOT-1051 dose-escalation trial evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. Preliminary data include the observation of an unconfirmed partial response in a patient with endometrial cancer at the 150 mg dose, with approximately 50% reduction in target lesion size and greater than 90% decrease in CA-125 levels. The study is currently enrolling patients in the 220 mg cohort, with a potential dose-response trend observed across the 70 mg, 100 mg, and 150 mg groups. Additional study updates are expected in the first half of 2026, and dose escalation is anticipated to be completed later in the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645027-en) on January 29, 2026, and is solely responsible for the information contained therein.